| Turkey | Thailand | South Korea | |
| Plasmapheresis | from AUD $1,726 | from AUD $3,164 | from AUD $6,041 |
| Therapeutic Apheresis | from AUD $1,942 | - | - |
| Plasma Exchange | from AUD $5,609 | - | - |
| DFPP Plasmapheresis | from AUD $2,661 | - | - |
Professor Zafer Gulbas is a leading hematologist-oncologist who founded the Bone Marrow Transplantation Center at Anadolu Medical Center.
Dr. Bulent Karagoz is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in immunotherapy and targeted therapies for sarcoma, lymphoma, and lung cancer. Dr. Karagoz provides treatment at a facility affiliated with the prestigious Johns Hopkins Hospital.
Professor Sevindik refined his haematology expertise at the Mayo Clinic – one of the world's most prestigious cancer research hospitals. He brings top-tier clinical training to his role at Istanbul Florence Nightingale Hospital.
Professor Bulent Eser is a leading haematology specialist at Medical Park Antalya with deep expertise in managing complex blood disorders.
Choose a Turkish hospital with JCI accreditation and a dedicated bone marrow transplant unit. Prioritise haematologists with experience in autologous stem cell transplants and CAR T-cell therapy. Leading Istanbul centres like Anadolu Medical Center maintain affiliations with top US institutions. This helps provide high care standards.
Bookimed Expert Insight: While many clinics offer general oncology, top-tier centres like Anadolu Medical Center and Medipol Mega University Hospital operate specialised bone marrow transplant units. Each has over 40 beds. Dr Zafer Gulbas alone has supervised 3,000+ transplants. For complex myeloma cases, this volume correlates with an 81% success rate for autologous procedures. This provides a significant safety margin for international patients.
Patient Consensus: Patients in Turkey describe an excellent experience with efficient staff and highly skilled doctors who follow evidence-based protocols. They recommend that patients choose a hospital with a dedicated international department. This department can handle practical needs like medical visas and airport transfers.
Patients can access comprehensive second opinions for myeloma at JCI-accredited Turkish centres. Specialists review diagnostic scans, bone marrow biopsies, and cytogenetic analysis to refine treatment paths. These evaluations often identify options for complex cases. These include CAR T-cell therapy or haploidentical stem cell transplantation.
Bookimed Expert Insight: Turkish haematologists are often more proactive with stem cell transplants for older patients. They offer these treatments more than other regions do. Dr Zafer Gulbas at Anadolu Medical Center reports an 81% success rate for autologous transplants. Patients whose treatment has stalled at home may find broader eligibility for intensive procedures here.
Patient Consensus: Patients note Turkey is a vital destination. This is especially when local protocols restrict stem cell transplants due to age. They emphasise that a second opinion there often reveals new paths. These include bispecific antibodies if standard induction therapies fail.
Turkey is a premier choice for myeloma care. This comes from a concentration of JCI-accredited hospitals. It also relies on specialists trained at leading global institutions. Centres provide stem cell transplantation and CAR T-cell therapy. They also use immunotherapies such as Keytruda to address refractory cases.
Bookimed Expert Insight: Data shows Turkish centres often serve as regional hubs for complex haematology. Hisar Hospital alone treats 250,000 patients annually. For Australians, the value is in high-volume expertise. Surgeons like Dr Osman Ilhan helped establish the Turkish national stem cell bank and hold multiple patents in cellular therapy. This suggests a level of innovation that rivals major Western university hospitals.
Patient Consensus: Patients value the efficiency and responsiveness of the medical staff in Istanbul. Many travellers note the support from personal co-ordinators makes navigating complex cancer protocols much simpler.
Patients in Turkey typically receive a comprehensive myeloma diagnosis within 3 to 7 days at private oncology centres. Major facilities in Istanbul provide fast-track diagnostic pathways. These include on-site PET-CT imaging, bone marrow biopsies, and blood analysis performed by JCI-accredited laboratories.
Bookimed Expert Insight: Turkish haematology centres like Anadolu Medical Center maintain affiliations with institutions like Johns Hopkins. This gives patients access to board-certified specialists. These specialists have handled thousands of complex blood cancer cases. Choosing an integrated hospital, not a general clinic, ensures diagnostic steps occur in one building. This coordination typically saves Australians 3 to 5 days compared to fragmented private care at home.
Patient Consensus: Patients note the efficiency and speed of Turkish staff when managing diagnostic tests. To avoid delays, travellers recommend bringing all prior blood test results and ultrasound images. This helps the local team start immediately.
Patients typically stay in Turkey for 3 to 6 months during the intensive phase of myeloma treatment. This period covers diagnostic workups, induction chemotherapy, and stem cell transplantation. Long-term maintenance therapy usually occurs at home in Australia. It uses oral medications under local specialist supervision.
Bookimed Expert Insight: While Turkey leads with 57,000+ international patient requests, success often depends on specialist volume. Dr Zafer Gulbas at Anadolu Medical Center has supervised 3,000+ transplants since 2010. Choosing such high-volume directors ensures protocol safety during the critical 8-week recovery window before returning to Australia.
Patient Consensus: Patients in Turkey suggest bringing a caretaker to manage strict dietary needs during recovery. They recommend booking accommodation with a kitchenette so all meals are prepared safely.